ArticleMolecular cancer therapeutics2011

Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.

Janice M Mehnert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.